15:30 – 16:00 – Michael Ponomarenko, InteCrypt B.V. and PimBio B.V.
Organ-on-a-chip’ technology: the return of human physiology
An ‘organ-on-a-chip’ device such as a microfluidic chip with microfluidic flow channels populated by living cells provides an accurate non-animal based alternative to traditional lab animal tests. OOC devices allow to perform cell-based experiments under in vivo like 3D conditions and is especially suited to the in vitro simulation of physiological cellular microenvironment. The short lecture will give information about physiology of cellular microenvironment of human body and the past, present and possible future of OOC technology.
About Michael Ponomarenko
Michael Ponomarenko has a unique combination of knowledge and skills in medicine and biomolecular sciences and is interested in development and commercialisation of microfluidic devices for in vitro reconstruction of complex living tissues. He has obtained his Master’s degree in Biomolecular Sciences in 2012 at VU University Amsterdam. His second Master’s internship in VU Medical Centre at Department of Dermatology (supervision Prof. Dr. Sue Gibbs) was focused on the full thickness skin tissue bioengineering to evaluate paracrine cytokine loops between two different cell types (mesenchymal-epidermal interactions). The Master’s thesis was about ECM-dependent and integrin-mediated endothelial cell biological responses in cardiovascular tissue engineering. It was clear to him that his passion is bioengineering of living tissues for different applications with a special focus on development of microfluidic devices. He is the author of 2 patents (international patent pending) and founder of two biotech companies InteCrypt B.V. (holding) and PimBio B.V. (daughter company), based in Pivot Park Oss (The Netherlands). PimBio B.V. is a SME company focused on development and commercialisation of micro-physiological devices incl. ‘organ-on-a-chip’ (OOC) technology for scientific and industrial needs. In collaboration with scientific and industrial partners he is involved in development of a ‘gut-on-a-chip’ in vitro system using human intestinal organoids for various applications such as safety and efficacy evaluation of food ingredients and development of high throughput screening cellular systems that could be used for massive parallel testing of individualized (combination) therapies.